Cholesterol drug may block melanoma spread in High-Risk patients
NCT ID NCT06157099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvastatin or a placebo for several years. The goal is to see if the drug can block the cancer's spread by reducing tumor cell movement and boosting the immune system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIA CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat cancers
- Experimental triple therapy for advanced cancers shows early promise but trial halted
- Melanoma survivors: new study tracks immunotherapy side effects
- Engineered virus takes on Hard-to-Treat melanoma
- Friends and fitness: key to life after cancer?
- Antibiotics before melanoma surgery: gut bacteria under the microscope